TokenPost·
Merck Ends Nemtabrutinib Development After Phase 3 Trial Review

A data monitoring committee raised concerns that the drug’s potential benefits might not outweigh its risks.
Every crypto headline. One feed. Updated every minute.

A data monitoring committee raised concerns that the drug’s potential benefits might not outweigh its risks.